AUPH earnings call for the period ending December 31, 2018.
News & Analysis: Aurinia Pharmaceuticals
It looks like an important patent that could protect its lead candidate is a done deal.
The pharma company bounced around for much of 2018, but there's intriguing potential in the pipeline.
Stock market slides are rarely kind to development-stage biopharma companies. Did October's sell-off create any opportunities for investors?
Steady progress for the company's experimental lupus treatment took an important step forward
An additional indication for the company's lead candidate has been a big source of encouragement.
Investors are excited about the potential for its lead drug to expand into additional diseases.
A planned expansion of its lead program has investors fired up.
Aurinia might make investors a lot of money. But there's no guarantee.
This small-cap biotech could be on the edge of something big.